CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 80 enrolled
Drug / intervention
vancomycin +2 moredrug
Likely dose
vancomycin 1gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02787057
NCT02787057N/ACompleted
CompareCT.gov

Intraperitoneal (IP) Vancomycin Plus Oral Moxifloxacin Versus IP Vancomycin Plus IP Ceftazidime for the Treatment of Peritoneal Dialysis-related Peritonitis: a Pilot Randomized Controlled Study

Peking University First Hospital·interventional·Posted Jun 1, 2016·Updated Mar 26, 2020

In Brief

A clinical study evaluating vancomycin, moxifloxacin, and 1 other intervention for Peritoneal Dialysis Associated Peritonitis. Completed, enrolled 80 participants.

Detailed Summary

Intra-peritoneal administration of antibiotics covering both gram-positive and gram-negative organisms was recommended as first-line regimen for the management of peritoneal dialysis related peritonitis. Oral administration of quinolones can also achieve effective serum concentrations, and is more convenient and economical. We conducted a pilot randomized controlled study to compare the effects on peritonitis cure and relapsing rates between oral moxifloxacin plus IP vancomycin and conventional IP vancomycin plus ceftazidime.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeritoneal Dialysis Associated Peritonitis
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 1, 2016
Enrollment StartNov 1, 2012
Primary CompletionApr 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 10.1 years ago

Interventions

vancomycindrug

IP vancomycin 1g every 5 days

moxifloxacindrug

oral moxifloxacin 400mg QD

ceftazidimedrug

IP ceftazidime 1g QD